FRANK FINE: Open Payments
NPI 1700981016 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,254 in 56 payments from 15 companies in 2025. Trend: 2023 $1,471 · 2024 $1,473 · 2025 $1,254
Food & beverage: $1,254
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $308 |
| Otsuka America Pharmaceutical, Inc. | 8 | $177 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $159 |
| Lundbeck LLC | 4 | $119 |
| Novo Nordisk Inc | 3 | $79 |
| PFIZER INC. | 5 | $76 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| Corcept Therapeutics | 3 | $63 |
| Electronic Waveform Lab, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
Products named: REXULTI, AIRSUPRA, Kerendia, Ozempic, ABILIFY MAINTENA, TRELEGY ELLIPTA, Korlym, NURTEC ODT.
Industry payments across CA — which companies pay providers there.
